Rosen Law Firm is reminding investors who purchased Unicycive Therapeutics securities during the December 29, 2025, through June 29, 2026, class period about a November 2, 2026, deadline to seek appointment as lead plaintiff in a securities class action. The lawsuit alleges Unicycive failed to inspect or audit a third-party manufacturing vendor and lacked a reasonable basis to believe the vendor had addressed deficiencies cited by the U.S. Food and Drug Administration. The complaint further alleges that undisclosed regulatory risks could delay approval of oxylanthanum carbonate, or OLC, and made the company's statements about its business and prospects materially misleading. The case has been filed, but no class has been certified. Investors may contact Rosen Law Firm through its website, by phone or email, and may remain absent class members without taking action.